Results 41 to 50 of about 28,682 (177)

Prevalence of BCR-ABL T315I Mutation in Different Chronic Myeloid Leukemia patients Categories.

Pakistan Journal of Biological Sciences, 2022
Background and Objective: Chronic Myelogenous Leukaemia (CML) is a clonal myeloproliferative tumor distinguished by the existence of the Philadelphia chromosome (Ph) resulting from the t (9, 22) (q34, q11) translocation.
Hala Elsir Khair, Babker Ahmed Mohamed, Bakri Yousef Nour, Hisham Ali Waggiallah   +3 more
semanticscholar   +1 more source

Mutational analysis of T315I in patients with chronic myeloid leukemia who did not respond to second-generation tyrosine kinase inhibitors

Iraqi Journal of Hematology, 2020
BACKGROUND: Chronic myelogenous leukemia (CML) is a hematological stem cell disorder that associates with mutations in BCR-ABL. Although mutations identified in more than 30 different amino acids, the highest degree of resistance was associated with ...
Riyam Qusay Ibrahim Al-Jadir, Jaffar Nouri Alalsaidissa   +1 more
doaj   +1 more source

Allogeneic stem cell transplant for chronic myeloid leukemia as a still promising option in the era of the new target therapy [PDF]

Vojnosanitetski Pregled, 2012
Background/Aim. Introducing tyrosine kinase inhibitors (TKIs) has essentially changed curative approach, to be precise, clearly improved treatment efficacy for chronic myeloid leukemia (CML).
Stamatović Dragana, Balint Bela, Tukić Ljiljana, Elez Marija, Tarabar Olivera, Todorović Milena, Todorić-Živanović Biljana, Ostojić Gordana, Tatomirović Željka, Marjanović Slobodan, Malešević Milomir   +10 more
doaj   +1 more source

Interferon-alpha-Treated Patients with Chronic Myelogenous Leukemia Show BCR/ABL-Positive Peripheral Blood Progenitor Cells Surviving Long-Term Culture

Folia Biologica, 2000
Several groups have shown that Ph-progenitors reappear in LTC of CML bone marrow or PBMNC when the cell preparations were derived from newly diagnosed Ph-positive patients or after induction chemotherapy. We have tested the hypothesis whether LTC may further decrease CML progenitors if the cells to be cultured were from IFN-treated
B, Schultheis, B, Heissig, G, Pasternak, S, Hörner, R, Hehlmann   +4 more
openaire   +2 more sources

Factors associated with achievement and durability of cytogenetic response in patients with chronic myeloid leukemia treated with imatinib [PDF]

Vojnosanitetski Pregled, 2011
Background/Aim. Imatinib mesylate, a selective Bcr-Abl tyrosine kinase inhibitor, has revolutionized the treatment of Bcr-Abl positive chronic myeloid leukemia and become the standard of care for this disease.
Ćojbašić Irena, Mačukanović-Golubović Lana   +1 more
doaj   +1 more source

Clinical Applications of Phosphoproteomics: Illuminating Cancer Signaling and Enabling Rational Therapeutic Strategies

Cancer Science, EarlyView.
Mass spectrometry‐based phosphoproteomics for mechanistic dissection of cancer signaling pathways and uncovering therapeutic vulnerabilities. ABSTRACT Protein phosphorylation is a central post‐translational modification regulating cellular signaling, frequently dysregulated in cancer.
Hirokazu Shoji, Narikazu Boku, Jun Adachi   +2 more
wiley   +1 more source

Monitoring of BCR-ABL levels in chronic myeloid leukemia patients treated with imatinib in the chronic phase: the importance of a major molecular response

Revista Brasileira de Hematologia e Hemoterapia, 2011
BACKGROUND: Real time PCR has become the most common technique to monitor BCR-ABL transcript levels of patients treated with kinase inhibitors. The aim of this study was to evaluate BCR-ABL levels of chronic myeloid leukemia patients treated with ...
Melissa Pereira Machado, Juarez Pires Tomaz, Irene Lorand-Metze, Cármino Antonio de Souza, Afonso Celso Vigorito, Marcia Torresan Delamain, Israel Bendit, Noemi Farah Pereira, Katia Borgia Barbosa Pagnano   +8 more
doaj   +1 more source

Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition

Journal of Hematology & Oncology, 2020
Background The Philadelphia chromosome (Ph), which leads to the creation and expression of the fusion gene product BCR-ABL, underlines the pathogenesis of chronic myelogenous leukemia (CML) and a fraction of adult and pediatric acute B-lymphoblastic ...
Xin-hua Xiao, Ping Liu, Donghe Li, Zhizhou Xia, Peihong Wang, Xiuli Zhang, Mingzhu Liu, L. Liao, B. Jiao, R. Ren   +9 more
semanticscholar   +1 more source

MXene‐Based Electrochemiluminescence (ECL) Biosensors: A Review on Analyte Detection and Diagnostic Applications

MedComm – Biomaterials and Applications, Volume 4, Issue 4, December 2025.
This review highlights recent advances in MXene‐based electrochemiluminescence (ECL) biosensors, showcasing their exceptional sensitivity and versatility in detecting biomolecules, pathogens, and environmental pollutants. The integration of MXenes significantly enhances ECL signal amplification, paving the way for next‐generation diagnostic and ...
Kai Zhang
wiley   +1 more source

Recommendations from a Portuguese Expert Group for Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients in Clinical Practice

Acta Médica Portuguesa, 2019
Until recently, the main goal of chronic myeloid leukemia therapy was disease control with the best overall survival, which required lifelong treatment.
Antonio Almeida, Francesca Pierdomenico, Blanca Polo Guerrero, Filipa Saraiva, Ana Montalvão, Jorge Coutinho, Mário Mariz, Teresa Melo, Maria João Santos, Alexandra Pereira, Nuno Cerveira   +10 more
doaj   +1 more source